Alnylam Pharmaceuticals
ALNY
#622
Rank
NZ$56.09 B
Marketcap
$434.87
Share price
2.75%
Change (1 day)
51.12%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$6.55

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$7.28. In 2022 the company made an earnings per share (EPS) of -$16.46 a decrease over its 2021 EPS that were of -$12.76.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$6.55-60.19%
2022-$16.4629.03%
2021-$12.76-3.36%
2020-$13.20-8.48%
2019-$14.427.67%
2018-$13.3939.74%
2017-$9.5912.94%
2016-$8.4938.84%
2015-$6.11-32.88%
2014-$9.11259.44%
2013-$2.53-31.25%
2012-$3.6952.94%
2011-$2.4130.77%
2010-$1.84-8.77%
2009-$2.0278.13%
2008-$1.13-70.78%
2007-$3.8899.09%
2006-$1.95-43.88%
2005-$3.47-82.33%
2004-$19.66-59.23%
2003-$48.21

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$3.01-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$66.19-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$13.87 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.48-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.99-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.63-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$5.63-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$3.54-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel